APA

Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Burmester G. R., Bijlsma J. W. J., Dougados M., Emery P., Keystone E. C., Klareskog L. & Mease P. J. (20051201). Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. : Annals of the rheumatic diseases.

Chicago

Furst D E, Breedveld F C, Kalden J R, Smolen J S, Burmester G R, Bijlsma J W J, Dougados M, Emery P, Keystone E C, Klareskog L and Mease P J. 20051201. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. : Annals of the rheumatic diseases.

Harvard

Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Burmester G. R., Bijlsma J. W. J., Dougados M., Emery P., Keystone E. C., Klareskog L. and Mease P. J. (20051201). Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. : Annals of the rheumatic diseases.

MLA

Furst D E, Breedveld F C, Kalden J R, Smolen J S, Burmester G R, Bijlsma J W J, Dougados M, Emery P, Keystone E C, Klareskog L and Mease P J. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. : Annals of the rheumatic diseases. 20051201.